Europe
Synthetic biology – an engineering approach to biological science– is gaining traction in biotechnology worldwide.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
Polyganics announced that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect.
Velabs Therapeutics GmbH, a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement with alytas therapeutics GmbH, for the development and commercialization of alytas’ antibodies in the field of senescence, related degenerative processes and pathologies.
A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
MiNA said the collaboration will combine its “expertise in the discovery and development of saRNA therapeutics” with AstraZeneca’s experience in “identifying and bringing breakthrough treatments to patients with metabolic diseases.”
The company said Fiasp is the “first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.”
The Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
Researchers benefit from faster FIB-SEM sample preparation, more accurate 3D tomography and greater integration in data reporting
This is a list of new molecular entities and new therapeutic biological products approved by the agency’s Center for Biologics Evaluation and Research in 2019.
PRESS RELEASES